Study for Reduction of Eye Pressure
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Registration Number
- CTRI/2021/01/030595
- Lead Sponsor
- iSTAR Medical SA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Males or females, 18 years of age or older.
Diagnosis of primary or secondary open angle glaucoma during
screening/baseline visit or earlier.
Grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45
degrees) according to Shaffer Angle Grading System.
Glaucoma not adequately controlled by one to four different topical
hypotensive medication(s), given each for at least one month, as
confirmed by 21mmHg
Patients must be willing and able to return for scheduled study-related examinations.
Patients must provide written informed consent.
Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) according to Shaffer Angle Grading System in the study eye.
Neovascular glaucoma in the study eye.
Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant in the stud eye.
Prior glaucoma surgery in the study eye. Patient treated with argon laser trabeculoplasty or selective laser trabeculoplasty in the study eye are eligible if treatment was performed ? 90 days before baseline visit in the study eye.
Visual field defect in the 10-degree central field in the study eye.
Any eye surgery that was performed ? 90 days before baseline visit in the study eye.
Anticipated need for ocular surgery or retinal laser procedure in the study eye 12 months following surgery in the study eye.
Anterior chamber anatomic configuration of high risk for development of angle closure glaucoma in the study eye.
Pre-existing ocular or systemic pathology that, in the opinion of the physician, is likely to cause postoperative complications following implantation of the device in the study eye.
Clinically significant corneal disease (e.g., corneal dystrophy) in the study eye.
Evidence of crystalline lens subluxation or luxation in the study eye.
Evidence of vitreous loss in the anterior chamber in the study eye.
Clinically significant intra-ocular inflammation or infection, presence of ocular disease such as uveitis, ocular infection, severe dry eye, severe blepharitis, active proliferative/inflammatory retinopathy in the
study eye.
Presence of silicone oil in the study eye.
Patients treated with systemic acetazolamide within 3 days before screening/baseline visit.
Patient with poor vision score: +1.0 in non-study eye, unless there is an expected benefit for the study eye in the opinion of the investigator.
Participation in any study involving an investigational drug or device within the past 3 months and planned participation to any other study during the present study.
Only for women of childbearing potential: positive blood pregnancy test at baseline visit.
Individuals under tutorship or trusteeship.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of the study is the proportion of patients with at least one serious ocular adverse event in the study eye, related to the device, occurring between 2 and 5 years after the MINIject implantation.Timepoint: The primary endpoint of the study is the proportion of patients with at least one serious ocular adverse event in the study eye, related to the device, occurring between 2 and 5 years after the MINIject implantation.
- Secondary Outcome Measures
Name Time Method Assessments will be evaluated for the study eye at all FU timepoints. <br/ ><br>Proportion of patients with greater than 30% ECD loss from pre-intervention baseline; patients who needed additional glaucoma surgeries to reduce IOP; who have 3 lines or more loss on BCVA as compared to the pre-intervention baseline; who have Visual Field defect AE <br/ ><br>Proportion of patients who have a �20% reduction in diurnal IOP from pre-intervention baseline <br/ ><br>Timepoint: 1) Follow-up at 3 Years <br/ ><br>2) Follow-up at 4 Years <br/ ><br>3) Follow-up at 5 Years